Michele Annette Gadd, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mastectomy, Segmental | 28 | 2023 | 956 | 2.150 |
Why?
|
Breast Neoplasms | 87 | 2023 | 20822 | 1.890 |
Why?
|
Mastectomy | 24 | 2023 | 1793 | 1.820 |
Why?
|
Carcinoma, Ductal, Breast | 16 | 2020 | 1101 | 1.070 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 15 | 2019 | 949 | 1.020 |
Why?
|
Sentinel Lymph Node Biopsy | 13 | 2020 | 709 | 0.850 |
Why?
|
Neoplasm, Residual | 6 | 2021 | 973 | 0.830 |
Why?
|
Mammaplasty | 11 | 2023 | 1204 | 0.770 |
Why?
|
Nipples | 9 | 2023 | 219 | 0.740 |
Why?
|
Carcinoma, Lobular | 12 | 2020 | 484 | 0.730 |
Why?
|
Carcinoma in Situ | 5 | 2019 | 806 | 0.650 |
Why?
|
Intraoperative Care | 4 | 2023 | 767 | 0.630 |
Why?
|
Peptide Hydrolases | 2 | 2021 | 634 | 0.610 |
Why?
|
Neoplasm Recurrence, Local | 20 | 2023 | 9239 | 0.550 |
Why?
|
Mastectomy, Subcutaneous | 4 | 2021 | 46 | 0.510 |
Why?
|
Neoplasm Staging | 24 | 2020 | 11031 | 0.500 |
Why?
|
Mammography | 14 | 2019 | 2476 | 0.490 |
Why?
|
Breast | 11 | 2020 | 1969 | 0.460 |
Why?
|
Breast Implantation | 3 | 2020 | 218 | 0.440 |
Why?
|
Lymph Node Excision | 13 | 2020 | 1261 | 0.420 |
Why?
|
Lymphatic Metastasis | 18 | 2016 | 2924 | 0.340 |
Why?
|
Axilla | 9 | 2020 | 595 | 0.300 |
Why?
|
Female | 104 | 2023 | 380194 | 0.250 |
Why?
|
Surgery, Computer-Assisted | 3 | 2023 | 1018 | 0.250 |
Why?
|
Emigration and Immigration | 2 | 2005 | 404 | 0.250 |
Why?
|
Follow-Up Studies | 29 | 2023 | 39050 | 0.220 |
Why?
|
Risk Assessment | 8 | 2020 | 23338 | 0.220 |
Why?
|
Middle Aged | 76 | 2023 | 213383 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
Retrospective Studies | 47 | 2023 | 77449 | 0.210 |
Why?
|
Mammary Glands, Human | 2 | 2014 | 199 | 0.210 |
Why?
|
Radiotherapy, Conformal | 3 | 2014 | 548 | 0.200 |
Why?
|
Lymph Nodes | 9 | 2020 | 3474 | 0.200 |
Why?
|
X-Ray Microtomography | 2 | 2013 | 428 | 0.190 |
Why?
|
Adult | 69 | 2021 | 214055 | 0.190 |
Why?
|
Cyclin D1 | 3 | 2001 | 463 | 0.190 |
Why?
|
Ataxia Telangiectasia | 1 | 2021 | 112 | 0.180 |
Why?
|
Mammary Glands, Animal | 1 | 2001 | 276 | 0.180 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.180 |
Why?
|
Melanoma | 10 | 2004 | 5510 | 0.180 |
Why?
|
Convalescence | 1 | 2020 | 105 | 0.180 |
Why?
|
Radio Frequency Identification Device | 1 | 2019 | 21 | 0.170 |
Why?
|
Aged | 55 | 2021 | 163280 | 0.170 |
Why?
|
Humans | 106 | 2023 | 744343 | 0.170 |
Why?
|
Postoperative Complications | 6 | 2020 | 15295 | 0.170 |
Why?
|
Neoplasm Invasiveness | 6 | 2020 | 3616 | 0.170 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2001 | 705 | 0.160 |
Why?
|
Patient Selection | 4 | 2020 | 4215 | 0.160 |
Why?
|
Prognosis | 16 | 2020 | 29063 | 0.160 |
Why?
|
Brachytherapy | 3 | 2012 | 1248 | 0.150 |
Why?
|
Cathepsins | 1 | 2018 | 241 | 0.150 |
Why?
|
Physical Exertion | 1 | 2020 | 695 | 0.150 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2021 | 547 | 0.140 |
Why?
|
Radiodermatitis | 2 | 2014 | 60 | 0.140 |
Why?
|
Surgical Flaps | 3 | 2020 | 1640 | 0.130 |
Why?
|
Reoperation | 6 | 2021 | 4201 | 0.130 |
Why?
|
Diagnostic Imaging | 2 | 2020 | 3507 | 0.130 |
Why?
|
Biopsy | 10 | 2022 | 6756 | 0.130 |
Why?
|
Photons | 3 | 2014 | 588 | 0.120 |
Why?
|
Skin Neoplasms | 9 | 2004 | 5686 | 0.120 |
Why?
|
Analgesics, Opioid | 2 | 2022 | 3674 | 0.120 |
Why?
|
Neoplasms, Second Primary | 2 | 2021 | 1061 | 0.120 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2021 | 1770 | 0.120 |
Why?
|
Aged, 80 and over | 26 | 2019 | 57776 | 0.120 |
Why?
|
Precancerous Conditions | 3 | 2017 | 975 | 0.120 |
Why?
|
Feasibility Studies | 3 | 2020 | 5078 | 0.120 |
Why?
|
Keratin-19 | 1 | 2013 | 33 | 0.110 |
Why?
|
Neoadjuvant Therapy | 3 | 2020 | 2728 | 0.110 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 1788 | 0.110 |
Why?
|
Receptors, Estrogen | 4 | 2016 | 2187 | 0.110 |
Why?
|
Fluorescent Dyes | 1 | 2020 | 1917 | 0.100 |
Why?
|
Data Mining | 1 | 2016 | 537 | 0.100 |
Why?
|
Sweden | 2 | 2005 | 1345 | 0.100 |
Why?
|
Survival Rate | 11 | 2016 | 12788 | 0.100 |
Why?
|
Anticarcinogenic Agents | 1 | 2012 | 253 | 0.100 |
Why?
|
Treatment Outcome | 21 | 2020 | 63114 | 0.090 |
Why?
|
Lymphedema | 2 | 2012 | 534 | 0.090 |
Why?
|
Chemoprevention | 1 | 2012 | 319 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2016 | 1524 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2016 | 3479 | 0.090 |
Why?
|
Pectoralis Muscles | 2 | 2020 | 82 | 0.090 |
Why?
|
Pain, Postoperative | 1 | 2019 | 1643 | 0.080 |
Why?
|
Costs and Cost Analysis | 2 | 2012 | 1681 | 0.080 |
Why?
|
Radiotherapy Dosage | 5 | 2021 | 2879 | 0.080 |
Why?
|
Incidence | 8 | 2019 | 20947 | 0.080 |
Why?
|
Genes, BRCA2 | 3 | 2008 | 618 | 0.080 |
Why?
|
Cardiovascular Diseases | 2 | 2005 | 15165 | 0.080 |
Why?
|
Extremities | 1 | 1993 | 865 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 1049 | 0.080 |
Why?
|
Prospective Studies | 14 | 2023 | 53288 | 0.080 |
Why?
|
Carcinoma, Ductal | 1 | 2008 | 101 | 0.080 |
Why?
|
Hyperplasia | 3 | 2017 | 1185 | 0.080 |
Why?
|
Genes, BRCA1 | 3 | 2008 | 781 | 0.080 |
Why?
|
BRCA2 Protein | 2 | 2023 | 794 | 0.070 |
Why?
|
Pneumonectomy | 1 | 1993 | 1094 | 0.070 |
Why?
|
Combined Modality Therapy | 7 | 2019 | 8642 | 0.070 |
Why?
|
Tumor Burden | 3 | 2019 | 1915 | 0.070 |
Why?
|
Monitoring, Intraoperative | 1 | 2013 | 957 | 0.070 |
Why?
|
Risk Factors | 15 | 2020 | 72290 | 0.070 |
Why?
|
Nomograms | 1 | 2008 | 228 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 934 | 0.070 |
Why?
|
Self Disclosure | 1 | 2007 | 251 | 0.070 |
Why?
|
Interferon-alpha | 2 | 2000 | 895 | 0.070 |
Why?
|
BRCA1 Protein | 2 | 2023 | 1149 | 0.060 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 3 | 1999 | 66 | 0.060 |
Why?
|
Intraoperative Period | 2 | 2018 | 520 | 0.060 |
Why?
|
Patient Satisfaction | 6 | 2021 | 3396 | 0.060 |
Why?
|
Soft Tissue Neoplasms | 1 | 1993 | 1363 | 0.060 |
Why?
|
SEER Program | 2 | 2019 | 1508 | 0.060 |
Why?
|
Thoracic Vertebrae | 1 | 2008 | 608 | 0.060 |
Why?
|
Cyclins | 2 | 1997 | 603 | 0.060 |
Why?
|
Poisson Distribution | 1 | 2005 | 513 | 0.060 |
Why?
|
Medical History Taking | 1 | 2007 | 783 | 0.060 |
Why?
|
Age Factors | 6 | 2021 | 18370 | 0.060 |
Why?
|
Fat Necrosis | 2 | 2014 | 58 | 0.060 |
Why?
|
Research Subjects | 1 | 2005 | 239 | 0.050 |
Why?
|
Age Distribution | 3 | 2005 | 2902 | 0.050 |
Why?
|
Mammary Tumor Virus, Mouse | 1 | 2001 | 61 | 0.050 |
Why?
|
Sarcoma | 1 | 1993 | 1897 | 0.050 |
Why?
|
Breast Implants | 2 | 2019 | 387 | 0.050 |
Why?
|
Oncogene Proteins | 2 | 1997 | 749 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 4 | 2017 | 35421 | 0.050 |
Why?
|
Spinal Neoplasms | 1 | 2008 | 760 | 0.050 |
Why?
|
Postoperative Period | 2 | 2020 | 1842 | 0.050 |
Why?
|
Genetic Testing | 3 | 2009 | 3444 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2016 | 19905 | 0.050 |
Why?
|
Young Adult | 9 | 2021 | 56430 | 0.050 |
Why?
|
Telangiectasis | 2 | 2014 | 76 | 0.050 |
Why?
|
Coloring Agents | 3 | 2016 | 566 | 0.050 |
Why?
|
Skin | 1 | 2014 | 4364 | 0.050 |
Why?
|
3T3 Cells | 1 | 2001 | 1101 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2016 | 4468 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2012 | 5391 | 0.040 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2000 | 141 | 0.040 |
Why?
|
Radiation Injuries | 2 | 2021 | 1180 | 0.040 |
Why?
|
Time Factors | 9 | 2020 | 40075 | 0.040 |
Why?
|
Calcinosis | 1 | 2008 | 1499 | 0.040 |
Why?
|
Lactation | 1 | 2001 | 412 | 0.040 |
Why?
|
Phyllodes Tumor | 1 | 1999 | 53 | 0.040 |
Why?
|
Acetates | 1 | 2000 | 311 | 0.040 |
Why?
|
Disclosure | 1 | 2005 | 736 | 0.040 |
Why?
|
Health Care Costs | 1 | 2012 | 3209 | 0.040 |
Why?
|
Regression Analysis | 2 | 2011 | 6459 | 0.040 |
Why?
|
Amines | 1 | 2000 | 276 | 0.040 |
Why?
|
Stereotaxic Techniques | 1 | 2001 | 536 | 0.040 |
Why?
|
Premenopause | 2 | 2016 | 1033 | 0.040 |
Why?
|
Tissue Expansion Devices | 1 | 2019 | 156 | 0.040 |
Why?
|
Sex Distribution | 1 | 2003 | 2297 | 0.040 |
Why?
|
Geographic Information Systems | 1 | 2020 | 281 | 0.040 |
Why?
|
Immunohistochemistry | 4 | 2018 | 11366 | 0.040 |
Why?
|
Esthetics | 2 | 2011 | 306 | 0.040 |
Why?
|
Anti-Anxiety Agents | 1 | 2000 | 390 | 0.040 |
Why?
|
Data Collection | 1 | 2007 | 3341 | 0.040 |
Why?
|
Radionuclide Imaging | 4 | 2008 | 2031 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 4 | 2008 | 17446 | 0.040 |
Why?
|
Surgical Mesh | 1 | 2020 | 276 | 0.040 |
Why?
|
Perceptual Distortion | 1 | 1996 | 35 | 0.040 |
Why?
|
Peptide Initiation Factors | 1 | 1996 | 56 | 0.040 |
Why?
|
Pilot Projects | 3 | 2020 | 8324 | 0.040 |
Why?
|
Antimanic Agents | 1 | 2000 | 522 | 0.040 |
Why?
|
Disease-Free Survival | 4 | 2016 | 6895 | 0.030 |
Why?
|
Tumor Cells, Cultured | 2 | 2001 | 6314 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2020 | 1590 | 0.030 |
Why?
|
Neoplasms | 2 | 2020 | 21683 | 0.030 |
Why?
|
Survival Analysis | 3 | 2017 | 10252 | 0.030 |
Why?
|
Preoperative Care | 2 | 2019 | 2250 | 0.030 |
Why?
|
Registries | 3 | 2007 | 8089 | 0.030 |
Why?
|
General Surgery | 2 | 1997 | 1636 | 0.030 |
Why?
|
Carcinoma, Merkel Cell | 1 | 1999 | 300 | 0.030 |
Why?
|
Perimenopause | 1 | 2016 | 139 | 0.030 |
Why?
|
Organ Specificity | 1 | 2020 | 2008 | 0.030 |
Why?
|
Antineoplastic Agents | 3 | 2005 | 13695 | 0.030 |
Why?
|
Device Removal | 1 | 2020 | 656 | 0.030 |
Why?
|
Tamoxifen | 2 | 2012 | 981 | 0.030 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1996 | 798 | 0.030 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2000 | 1121 | 0.030 |
Why?
|
Heterozygote | 1 | 2021 | 2804 | 0.030 |
Why?
|
Cell Division | 1 | 2001 | 4568 | 0.030 |
Why?
|
Treatment Failure | 2 | 2013 | 2618 | 0.030 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 15076 | 0.030 |
Why?
|
Foot | 1 | 1997 | 527 | 0.030 |
Why?
|
Male | 16 | 2020 | 350118 | 0.030 |
Why?
|
Postmenopause | 2 | 2016 | 2461 | 0.030 |
Why?
|
Groin | 1 | 1992 | 104 | 0.030 |
Why?
|
Radiation Pneumonitis | 1 | 2013 | 104 | 0.030 |
Why?
|
Ovarian Neoplasms | 2 | 2007 | 4838 | 0.030 |
Why?
|
Skin Pigmentation | 1 | 2014 | 282 | 0.030 |
Why?
|
Genetic Vectors | 1 | 2001 | 3420 | 0.030 |
Why?
|
Radiopharmaceuticals | 2 | 1999 | 2645 | 0.030 |
Why?
|
Mutation | 4 | 2023 | 29786 | 0.030 |
Why?
|
Hand | 1 | 1997 | 884 | 0.030 |
Why?
|
Mutation, Missense | 1 | 2021 | 2564 | 0.020 |
Why?
|
Relative Biological Effectiveness | 1 | 2013 | 323 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2005 | 7913 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 1996 | 987 | 0.020 |
Why?
|
Androstadienes | 1 | 2012 | 346 | 0.020 |
Why?
|
Preventive Medicine | 1 | 2012 | 264 | 0.020 |
Why?
|
Head and Neck Neoplasms | 3 | 2001 | 2734 | 0.020 |
Why?
|
Cyanoacrylates | 1 | 2010 | 49 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2001 | 3617 | 0.020 |
Why?
|
Neoplasm Metastasis | 2 | 2016 | 4851 | 0.020 |
Why?
|
Lymphatic Irradiation | 1 | 2010 | 103 | 0.020 |
Why?
|
Photography | 1 | 2013 | 520 | 0.020 |
Why?
|
Skin, Artificial | 1 | 2010 | 90 | 0.020 |
Why?
|
Receptors, Progesterone | 2 | 2010 | 1097 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2925 | 0.020 |
Why?
|
Age of Onset | 1 | 2016 | 3271 | 0.020 |
Why?
|
Arm | 1 | 2012 | 589 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 1993 | 13102 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2001 | 9734 | 0.020 |
Why?
|
Tissue Expansion | 1 | 2010 | 162 | 0.020 |
Why?
|
Tissue Adhesives | 1 | 2010 | 179 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2012 | 12245 | 0.020 |
Why?
|
Early Detection of Cancer | 2 | 2015 | 3086 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2005 | 13989 | 0.020 |
Why?
|
Bandages | 1 | 2010 | 266 | 0.020 |
Why?
|
Pregnancy | 2 | 2019 | 29144 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2459 | 0.020 |
Why?
|
False Negative Reactions | 2 | 1999 | 588 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2005 | 6364 | 0.020 |
Why?
|
Research | 1 | 1996 | 1999 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2016 | 7279 | 0.020 |
Why?
|
Microcomputers | 1 | 2007 | 147 | 0.020 |
Why?
|
Cohort Studies | 3 | 2014 | 40561 | 0.020 |
Why?
|
Receptor, erbB-2 | 2 | 2010 | 2416 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6538 | 0.020 |
Why?
|
Internship and Residency | 2 | 1997 | 5788 | 0.020 |
Why?
|
Recurrence | 2 | 2001 | 8340 | 0.020 |
Why?
|
Length of Stay | 1 | 2019 | 6309 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1531 | 0.020 |
Why?
|
Sensitivity and Specificity | 3 | 2007 | 14722 | 0.020 |
Why?
|
Decision Making | 1 | 2019 | 3887 | 0.020 |
Why?
|
Matched-Pair Analysis | 1 | 2005 | 288 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 1996 | 5867 | 0.020 |
Why?
|
Fibrosis | 1 | 2011 | 2029 | 0.020 |
Why?
|
Electrons | 1 | 2006 | 268 | 0.020 |
Why?
|
Cicatrix | 1 | 2010 | 764 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2008 | 604 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2001 | 11483 | 0.020 |
Why?
|
Iridium Radioisotopes | 1 | 2003 | 26 | 0.010 |
Why?
|
Carcinoma | 1 | 1995 | 2375 | 0.010 |
Why?
|
Exercise | 1 | 2020 | 5615 | 0.010 |
Why?
|
Bipolar Disorder | 1 | 2000 | 5027 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 1996 | 3843 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 11524 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1405 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 7023 | 0.010 |
Why?
|
Collagen | 1 | 2010 | 2689 | 0.010 |
Why?
|
Adolescent | 5 | 2001 | 85781 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 7729 | 0.010 |
Why?
|
Radiotherapy | 1 | 2008 | 1533 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6365 | 0.010 |
Why?
|
Aromatase Inhibitors | 1 | 2005 | 491 | 0.010 |
Why?
|
Technetium | 1 | 2001 | 334 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2006 | 2886 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 2000 | 6622 | 0.010 |
Why?
|
ROC Curve | 1 | 2008 | 3527 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1257 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 3508 | 0.010 |
Why?
|
Primary Prevention | 1 | 2007 | 1167 | 0.010 |
Why?
|
Gamma Rays | 1 | 2001 | 320 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1995 | 8428 | 0.010 |
Why?
|
Logistic Models | 2 | 2008 | 13408 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 12804 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 1996 | 9648 | 0.010 |
Why?
|
Proportional Hazards Models | 2 | 2005 | 12354 | 0.010 |
Why?
|
Gamma Cameras | 1 | 1998 | 36 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1996 | 12072 | 0.010 |
Why?
|
Antibodies, Neoplasm | 1 | 1999 | 286 | 0.010 |
Why?
|
Self-Evaluation Programs | 1 | 1997 | 29 | 0.010 |
Why?
|
Perioperative Care | 1 | 2005 | 1002 | 0.010 |
Why?
|
Breast Self-Examination | 1 | 1997 | 34 | 0.010 |
Why?
|
Uterine Neoplasms | 1 | 2007 | 1513 | 0.010 |
Why?
|
Physicians | 1 | 1996 | 4567 | 0.010 |
Why?
|
Risk | 1 | 2010 | 9687 | 0.010 |
Why?
|
Decision Trees | 1 | 1999 | 506 | 0.010 |
Why?
|
Pedigree | 1 | 2005 | 4644 | 0.010 |
Why?
|
Upstream Stimulatory Factors | 1 | 1996 | 20 | 0.010 |
Why?
|
Educational Status | 1 | 2005 | 2540 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2003 | 2242 | 0.010 |
Why?
|
RNA Caps | 1 | 1996 | 74 | 0.010 |
Why?
|
Doxorubicin | 1 | 2003 | 2234 | 0.010 |
Why?
|
Eukaryotic Initiation Factor-4E | 1 | 1996 | 107 | 0.010 |
Why?
|
Attitude to Health | 1 | 2005 | 2052 | 0.010 |
Why?
|
Mass Screening | 2 | 2005 | 5255 | 0.010 |
Why?
|
Paclitaxel | 1 | 2003 | 1708 | 0.010 |
Why?
|
Base Sequence | 2 | 1997 | 12797 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1997 | 1581 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9313 | 0.010 |
Why?
|
Body Mass Index | 1 | 2012 | 12720 | 0.010 |
Why?
|
Mice | 1 | 2001 | 81183 | 0.010 |
Why?
|
Mood Disorders | 1 | 2000 | 1106 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1997 | 18111 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1997 | 2050 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 12959 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1996 | 1723 | 0.010 |
Why?
|
Software | 1 | 2007 | 4443 | 0.010 |
Why?
|
Transcription, Genetic | 2 | 1997 | 7722 | 0.010 |
Why?
|
Massachusetts | 1 | 2005 | 8663 | 0.010 |
Why?
|
Animals | 2 | 2001 | 168757 | 0.010 |
Why?
|
Alternative Splicing | 1 | 1997 | 1117 | 0.010 |
Why?
|
Models, Biological | 1 | 2008 | 9583 | 0.010 |
Why?
|
Family Health | 1 | 1996 | 1282 | 0.010 |
Why?
|
United States | 1 | 2019 | 69872 | 0.010 |
Why?
|
HeLa Cells | 1 | 1996 | 3128 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 1995 | 1758 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 1996 | 2126 | 0.010 |
Why?
|
Transfection | 1 | 1996 | 5892 | 0.000 |
Why?
|
Recombinant Fusion Proteins | 1 | 1996 | 3772 | 0.000 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2000 | 10943 | 0.000 |
Why?
|
Blotting, Western | 1 | 1995 | 5179 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1997 | 6171 | 0.000 |
Why?
|
Colorectal Neoplasms | 1 | 2007 | 6773 | 0.000 |
Why?
|
Patient Education as Topic | 1 | 1997 | 2278 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2007 | 25043 | 0.000 |
Why?
|
Models, Genetic | 1 | 1996 | 3494 | 0.000 |
Why?
|
Fibroblasts | 1 | 1996 | 4161 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 2003 | 9274 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1997 | 13815 | 0.000 |
Why?
|
Curriculum | 1 | 1997 | 3605 | 0.000 |
Why?
|
Cell Line | 1 | 1996 | 15997 | 0.000 |
Why?
|
Anxiety | 1 | 1996 | 4297 | 0.000 |
Why?
|
Clinical Competence | 1 | 1997 | 4687 | 0.000 |
Why?
|
Depression | 1 | 2000 | 7766 | 0.000 |
Why?
|
Rats | 1 | 1996 | 24260 | 0.000 |
Why?
|
Primary Health Care | 1 | 1996 | 4558 | 0.000 |
Why?
|
Transcription Factors | 1 | 1996 | 12208 | 0.000 |
Why?
|
Child | 1 | 2001 | 77709 | 0.000 |
Why?
|